Oral Arsenic Trioxide for NPM1-mutated AML

计划入组 50 人 · 首次发布于 2020 年 12 月 30 日

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

计划入组 15 人 · 首次发布于 2021 年 8 月 25 日

Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.

计划入组 100 人 · 首次发布于 2021 年 6 月 18 日

AML mRNA multivalent LPP nanoparticle vaccine (Stemirna Therapeutics/Ruijin Hospital)

PanAd3-NPM1

AML-3

BEAT AML, LLC

United States

Bio-Path Holdings

United States

Aprea Therapeutics

United States

Kura Oncology's Ziftomenib Receives FDA Priority Review for NPM1-Mutant AML, PDUFA Date Set for November 2025

FDA Accepts Kura Oncology's NDA for Ziftomenib in NPM1-Mutant AML with Priority Review

Kura Oncology and Kyowa Kirin Collaborate to Advance Ziftomenib for AML Treatment